Clinical Trial Results:
A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.
Summary
|
|
EudraCT number |
2004-002502-29 |
Trial protocol |
GB IT HU |
Global completion date |
28 Aug 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Nov 2016
|
First version publication date |
03 Nov 2016
|
Other versions |
|
Summary report(s) |
CT.gov Summary Results - Study 206207-009 - Eudra 2004-002502-29 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.